Magnesium isoglycyrrhizinate remodels the inflammatory tumor microenvironment in gastric cancer through inhibition of the phospholipase A2 (PLA2)/nuclear factor κB (NF-κB) signaling axis
Cancer Pathogenesis and Therapy · 2026-11 · 4 (6) · 507-520
DOI: 10.1016/j.cpt.2026.06.001 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Pathogenesis and Therapy, 2026-11. Verfasst von Yuqing Miao und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, Changzheng Hospital, Naval Medical University, Shanghai 200003, China. Die Arbeit nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Background
Chronic inflammation drives tumor progression by fostering an immunosuppressive tumor microenvironment (TME). Phospholipase A2 (PLA2) contributes to this process through the generation of bioactive lipid mediators. The present study investigated the efficacy and mechanism of magnesium isoglycyrrhizinate (MgIG), a clinical PLA2 inhibitor with anti-tumor potential, in remodeling the inflammatory TME of gastric cancer.
Methods
Murine gastric cancer (MFC) syngeneic allografts were established in mice to evaluate the anti-tumor effects of MgIG. Cell viability was examined in MFC and human gastric adenocarcinoma (AGS) cell lines. Cytokine and chemokine expression in the tumors was quantified by quantitative real-time polymerase chain reaction (qRT-PCR). Key immune cell infiltration within the TME was assessed via immunohistochemistry (IHC). Western blotting was used to investigate the downstream effects of MgIG on signaling pathways. Conditioned medium (CM) from MgIG-treated tumor cells was used to culture murine macrophage (RAW264.7) and human monocytic leukemia (THP-1) cell lines, and polarization markers were analyzed by Western blotting, immunofluorescence (IF), and enzyme-linked immunosorbent assay (ELISA). Overexpression of phospholipase A2 group IVA (Pla2g4a in MFC cells and PLA2G4A in AGS cells) was performed to validate the mechanistic pathway. Comparisons were performed using Student's t test or analysis of variance (ANOVA). Survival differences were assessed by the log-rank test.
Results
MgIG significantly suppressed the growth of MFC gastric cancer allografts, as evidenced by reduced tumor volume and weight (both P < 0.05). Additionally, it prolonged the survival of tumor-bearing mice (P < 0.0001) without inducing hepatotoxicity or gastric tissue damage (alanine aminotransferase [ALT], P = 0.7482; aspartate aminotransferase [AST], P = 0.3293). Mechanistically, MgIG induced treatment-specific regulation of inflammatory mediators within the TME, including reductions in the expression of C-X-C motif chemokine ligand 1 (Cxcl1), interleukin 10 (Il10), Il23a, and key nodes in the toll-like receptor 4 (Tlr4)/Tlr6-myeloid differentiation primary response gene 88 (Myd88)-nuclear factor κB (NF-κB) pathway (P < 0.05). Molecular docking suggested a potential interaction between MgIG and PLA2G4A, which was associated with the reduced activation of the NF-κB pathway and p65 nuclear translocation (P < 0.05). Furthermore, MgIG reshaped the immune landscape by increasing the infiltration of CD8+ T cells and macrophages while reducing regulatory T cell (Treg) infiltration (P < 0.05). Crucially, CM from MgIG-treated tumor cells polarized tumor-associated macrophages (TAMs) from an M2-like toward an M1-like phenotype, characterized by elevated inducible nitric oxide synthase (iNOS) and IL-12A expression and decreased arginase-1 (Arg-1) and cluster of differentiation 206 / mannose receptor (CD206) levels (P < 0.05). This polarization shift was associated with PLA2-NF-κB signaling, as mouse Pla2g4a or human PLA2G4A overexpression reversed the MgIG-induced M1-like polarization (P < 0.05).
Conclusions
MgIG suppresses gastric cancer progression by remodeling the inflammatory TME, thereby enhancing anti-tumor immunity and inhibiting immune evasion. MgIG enhances cytotoxic T-cell infiltration and, critically, reverses macrophage polarization from an M2-like to an M1-like phenotype, potentially via inhibition of the PLA2-NF-κB signaling axis, with associated suppression of the TLR-MyD88 pathway. These findings suggest that MgIG possesses immunomodulatory functions and indicate its potential as a therapeutic strategy for suppressing inflammation-driven gastric cancer, warranting further clinical investigation.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Oncology, Changzheng Hospital, Naval Medical University, Shanghai 200003, China.
- Department of Respiratory Medicine, The Sixth People's Hospital of Nantong, Affiliated Nantong Hospital of Shanghai University, Nantong, Jiangsu 226011, China.
- National Key Laboratory of Immunity & Inflammation, Institute of Immunology, Naval Medical University, Shanghai 200433, China.
- Department of Gastrointestinal Surgery, Changzheng Hospital, Naval Medical University, Shanghai 200003, China.
- Department of Oncology, Naval Medical Center, Naval Medical University, Shanghai 200052, China.
Zitieren
APA
Miao, Y., Li, Z., Dong, F., Jiang, C., Tang, Y., Chen, T., Wang, J., & Zhou, W. (2026). Magnesium isoglycyrrhizinate remodels the inflammatory tumor microenvironment in gastric cancer through inhibition of the phospholipase A2 (PLA2)/nuclear factor κB (NF-κB) signaling axis. Cancer Pathogenesis and Therapy, 4(6), 507-520. https://doi.org/10.1016/j.cpt.2026.06.001
Vancouver
Miao Y, Li Z, Dong F, Jiang C, Tang Y, Chen T, et al. Magnesium isoglycyrrhizinate remodels the inflammatory tumor microenvironment in gastric cancer through inhibition of the phospholipase A2 (PLA2)/nuclear factor κB (NF-κB) signaling axis. Cancer Pathogenesis and Therapy. 2026;4(6):507-520. doi:10.1016/j.cpt.2026.06.001
BibTeX
@article{Miao2026,
author = {Miao, Yuqing and Li, Zheng and Dong, Fangyuan and Jiang, Chang and Tang, Yuan and Chen, Taoyong and Wang, Jiejun and Zhou, Wenli},
title = {Magnesium isoglycyrrhizinate remodels the inflammatory tumor microenvironment in gastric cancer through inhibition of the phospholipase A2 (PLA2)/nuclear factor κB (NF-κB) signaling axis},
journal = {Cancer Pathogenesis and Therapy},
year = {2026},
volume = {4},
number = {6},
pages = {507--520},
doi = {10.1016/j.cpt.2026.06.001}
}
EUVIMED